Dr. Juengling is a tenured professor at the Department of Oncology, University of Alberta, where he holds the Dr. Anthony Noujaim Endowed Chair of Oncology at the Faculty of Medicine and Dentistry. He is Director of the Division of Oncologic Imaging of the University of Alberta, and also leads the PET/MR program at the Cross Cancer Institute, Edmonton. He is member of the Neuroscience and Mental Health Institute (NMHI) and of the Cancer Research Institute of Northern Alberta (CRINA) at the University of Alberta. He is also associate Faculty (Privatdozent) for Nuclear Medicine at University Berne, Switzerland, where he performed sustained research in standardisation and quantification of PET/CT, and serves as associate Editor for peer-reviewed Journals including Frontiers Oncology and Frontiers Neurology. He has been long-time co-chair of the tariff commission of the Swiss Society of Nuclear Medicine and Molecular Imaging. He has been a visiting fellow at the Institute of Neurology, Queens Square, London and a visiting scientist at the surgical planning lab, Brigham & Women’s Hospital, Boston. Previously, Dr. Juengling had directed the PET/CT Center Northwest Switzerland and the Department of Nuclear Medicine at St. Clara Hospital, Basel, Switzerland since 2007, which he had developed into a major, regional provider for oncological PET/CT imaging, servicing as well the local center for surgical and medical oncology and outpatients referred by secondary specialists. Dr. Juengling has authored and co-authored over 150 publications in correlative imaging using MRI, MR-Spectroscopy, voxel-based morphometry, SPECT, PET, PET/CT, SPECT/CT and PET/MRI with a broad spectrum in clinical applications and a special focus in neuroimaging, behavioural neurosciences and in oncology. He received the Marie Curie Award of the European Association of Nuclear Medicine in 2002 for research using hybrid PET/MR imaging of the dopamine pathway and neuronal degeneration in Huntington’s Disease. Dr. Juengling is a funded investigator of governmental and non-governmental resources and has been a collaborating scientist for multimodal PET Analysis with Siemens Molecular Imaging, Oxford. He has a long history as active member of several Task forces and committees of the Swiss Society of Nuclear Medicine, and, more lately, the Canadian Society of Nuclear Medicine. His current clinical and research interests include translational medicine approaches for new tumor peptides suitable for theranostics as well as the biomarker imaging of new aspects of neurodegenerative and neuroinflammatory disease. Prior research had focused on optimization of single breathhold imaging in oncologic PET/CT, dual-timepoint imaging in pancreatic cancer, application of PET/MR and PET/CT in primary and secondary liver disease and characterization of inflammatory joint disease in SPECT/CT and SPECT/MR. As part of his current clinical activities, he is serving at the Cross Cancer Institute, Edmonton and at Alberta Health Services as physician-scientist performing 68-Ga-DOTATE PET/MR diagnostics and 177-Lu-DOTATATE treatment for neuroendocrine tumors, and is investigating experimental therapy and future applications of Peptide Receptor Radionuclide Therapy (PRRT).